The 2025 Prostate Cancer International Symposium (PCIS25) Concludes Successfully
2025 Prostate Cancer International Symposium (PCIS25) Concludes with Global Insights on Therapy Resistance
International experts gather in Taipei to tackle challenges in prostate cancer research and treatment
The 2025 Prostate Cancer International Symposium (PCIS25) was successfully held on April 9–10, 2025, at Taipei Medical University (TMU). Co-organized by the College of Medical Science and Technology, TMU Hospital, and the Taipei Cancer Center, the two-day event brought together more than 150 researchers, clinicians, and scholars from around the world to explore the latest advances in prostate cancer treatment and resistance mechanisms.
With the theme “Prostate Cancer Therapy Resistance: The Genetic, Epigenetic, and Metabolic Connections,” the symposium focused on molecular biology, epigenetics, and metabolic pathways that contribute to therapy resistance, aiming to advance precision medicine and foster innovative treatment strategies.
🌐 World-Leading Experts Share the Stage
The symposium welcomed internationally renowned experts from top academic institutions, including:
Dr. William Nelson (Johns Hopkins University)
Dr. Angelo DeMarzo (Johns Hopkins University)
Dr. Jiaoti Huang (Duke University)
Dr. Himisha Beltran (Dana-Farber Cancer Institute / Harvard Medical School)
Dr. Colin Collins & Dr. Yuzhuo Wang (University of British Columbia)
Dr. Allen Gao & Dr. Hongwu Chen (University of California, Davis)
Dr. Hsing-Jien Kung, Academician and Chair Professor at TMU
These distinguished speakers presented research on topics ranging from neuroendocrine differentiation and genetic mutations to AR signaling, immune-based therapies, and epigenetic plasticity in prostate cancer.
🧬 Thematic Depth and Collaborative Exchange
PCIS25 featured six thematic tracks:
Neuroendocrine Differentiation, Epigenetics, Genetics, Prostate Cancer Progression, Therapy Resistance, and Novel Therapy.
Over 20 keynote and invited talks were delivered, with active participation from leading Taiwanese research institutions, including Academia Sinica, National Health Research Institutes (NHRI), Chang Gung University, and Taipei Medical University.
The symposium highlighted Taiwan’s growing role in global prostate cancer research and fostered valuable opportunities for international collaboration.
🏛 Cultural Engagement: Connecting Through Experience
In addition to academic discussions, participants enjoyed a Welcome Dinner and an optional City Tour, which included visits to the National Palace Museum, Shilin Official Residence, and a fine lunch at Silks Palace, offering a glimpse into Taiwan’s rich cultural heritage and warm hospitality.
📝 Organizers & Acknowledgment
PCIS25 was co-chaired by:
Dr. Shauh-Der Yeh, Director, TMU Hospital Cancer Center
Dr. Yen-Nien Liu, Distinguished Professor, Director of the Graduate Institute of Cancer Biology and Drug Discovery
Dr. Hsing-Jien Kung, Chair Professor, College of Medical Science and Technology, TMU
The organizing committee extends heartfelt thanks to all speakers, moderators, participants, and support staff for making this symposium a resounding success.
